Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

ATHA

Athira Pharma Inc

May 17 • 04:00PM ET

2.52

Dollar change -0.19
Percentage change -7.01	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: SURI VTI VXF SMLF DFAT IWC AVSC DFAS DFAC DCOR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.05	Insider Own	7.90%	Shs Outstand	38.17M	Perf Week	18.87%
Market Cap	96.59M	Forward P/E	-	EPS next Y	-2.46	Insider Trans	24.32%	Shs Float	35.30M	Perf Month	22.33%
Income	-116.19M	PEG	-	EPS next Q	-0.76	Inst Own	56.89%	Short Float	2.98%	Perf Quarter	-29.61%
Sales	0.00M	P/S	-	EPS this Y	5.95%	Inst Trans	0.84%	Short Ratio	3.10	Perf Half Y	58.49%
Book/sh	2.79	P/B	0.90	EPS next Y	15.30%	ROA	-63.45%	Short Interest	1.05M	Perf Year	-8.70%
Cash/sh	3.19	P/C	0.79	EPS next 5Y	-	ROE	-73.11%	52W Range	1.33 - 4.30	Perf YTD	3.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-81.69%	ROI	-107.72%	52W High	-41.37%	Beta	2.94
Dividend TTM	-	Quick Ratio	5.03	Sales past 5Y	0.00%	Gross Margin	-	52W Low	89.47%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	5.03	EPS Y/Y TTM	-12.48%	Oper. Margin	0.00%	RSI (14)	58.23	Volatility	10.92% 6.91%
Employees	67	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	7.28
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	6.31%	Payout	-	Rel Volume	0.53	Prev Close	2.71
Sales Surprise	-	EPS Surprise	13.63%	Sales Q/Q	-	Earnings	May 15 AMC	Avg Volume	339.09K	Price	2.52
SMA20	19.80%	SMA50	5.85%	SMA200	4.93%	Trades		Volume	180,056	Change	-7.01%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-17-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$20
Jul-07-22	Initiated	Mizuho	Buy	$6
Jun-23-22	Downgrade	Stifel	Buy → Hold	$36 → $5
Jun-23-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-23-22	Downgrade	Jefferies	Buy → Hold	$32 → $3
May-10-22	Initiated	BTIG Research	Buy	$33
Apr-21-22	Initiated	Berenberg	Buy	$33
Dec-15-21	Initiated	Goldman	Neutral	$16
Oct-13-20	Initiated	Stifel	Buy	$36
Oct-13-20	Initiated	JMP Securities	Mkt Outperform	$51
Oct-13-20	Initiated	Jefferies	Buy	$30
Oct-13-20	Initiated	Goldman	Buy	$53

Show Previous Ratings

May-17-24 05:00PM	Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action (GlobeNewswire) -7.01%
May-15-24 10:54PM	ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) +10.66%
May-02-24 07:00AM	Athira Pharma to Participate in Upcoming May Conferences (GlobeNewswire)
07:00AM	Loading…
Apr-15-24 07:00AM	Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer (GlobeNewswire) -15.57%
Apr-11-24 07:00AM	Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease (GlobeNewswire) +6.85%
Apr-03-24 07:00AM	Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Mar-08-24 07:00AM	Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD 2024 International Conference (GlobeNewswire) -13.73%
Feb-28-24 12:00PM	Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-22-24 04:05PM	Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +6.22%
Feb-15-24 02:56PM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks) +12.27%
Feb-08-24 04:02PM	Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Jan-08-24 07:00AM	Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update (GlobeNewswire) +10.45%
Jan-03-24 07:00AM	Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire)
07:00AM	Loading…
Dec-12-23 07:00AM	Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies (GlobeNewswire)
Dec-05-23 10:25AM	Sidoti Events, LLC's Virtual December Small-Cap Conference (ACCESSWIRE)
Nov-29-23 07:00AM	Athira Pharma to Participate in Sidoti December Small Cap Investor Conference (GlobeNewswire)
Nov-28-23 07:00AM	Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association's 34 International Symposium on ALS/MND (GlobeNewswire) -5.88%
Nov-15-23 08:15AM	Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid- -Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease (GlobeNewswire)
Nov-09-23 04:05PM	Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) -7.33%
Nov-08-23 07:00AM	Athira Pharma to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Oct-05-23 04:30PM	Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Sep-28-23 07:00AM	Athira Pharma to Participate in Upcoming October Conferences (GlobeNewswire) +5.26%
Sep-19-23 07:00AM	Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-08-23 12:00PM	All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy (Zacks)
Aug-31-23 09:35AM	Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA) (Zacks)
Aug-29-23 09:55AM	Athira Pharma, Inc. (ATHA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-10-23 04:05PM	Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +5.21%
Jul-17-23 07:00AM	Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimers Disease (GlobeNewswire)
11:52AM	Loading…
Jul-06-23 11:52AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
07:00AM	Athira Pharma Announces Upcoming Presentations at the Alzheimers Association International Conference (AAIC) 2023 (GlobeNewswire)
Jun-08-23 06:08AM	Andrew Gengos Spends US$192k On Athira Pharma Stock \ (Simply Wall St.)
Jun-07-23 08:10AM	Daily Vickers Top Buyers & Sellers for 06/07/2023 (Argus Research) +12.54%
May-31-23 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-22-23 07:00AM	Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer (GlobeNewswire)
May-12-23 11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
May-11-23 04:05PM	Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
May-08-23 07:00AM	Athira Pharma to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-29-23 08:45AM	Athira Pharma, Inc. (NASDAQ:ATHA) is a favorite amongst institutional investors who own 58% (Simply Wall St.)
Apr-25-23 04:01PM	Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-11-23 07:00AM	Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-02-23 08:14AM	Trade Alert: The Independent Director Of Athira Pharma, Inc. (NASDAQ:ATHA), Grant Pickering, Has Just Spent US$60k Buying 3,193% More Shares (Simply Wall St.)
Mar-28-23 12:00PM	Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
01:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimers and Parkinsons Diseases at AD/PD 2023 International Conference (GlobeNewswire)
Mar-23-23 04:05PM	Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
Mar-08-23 07:00AM	Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences (GlobeNewswire)
Mar-06-23 07:00AM	Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences (GlobeNewswire)
Feb-01-23 07:00AM	Athira Pharma Announces Publication in Journal of Alzheimers Disease Highlighting Need for Novel Alzheimers Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway (GlobeNewswire)
Jan-31-23 07:00AM	Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer (GlobeNewswire)
Jan-28-23 08:00AM	How Athira and its former CEO are moving on after controversial split (American City Business Journals)
Jan-27-23 10:08AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-17-23 01:00AM	Former Athira CEO on her controversial exit: 'I was relieved that it came to an end' (American City Business Journals)
Jan-05-23 07:00AM	Athira Pharma Provides 2023 Pipeline Outlook (GlobeNewswire)
Jan-03-23 06:26AM	Daily Vickers Top Buyers & Sellers for 01/03/2023 (Argus Research) +6.62%
Dec-21-22 07:00AM	Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics (GlobeNewswire)
Dec-09-22 05:34AM	Insider Buying: The Athira Pharma, Inc. (NASDAQ:ATHA) Independent Chairwoman of the Board Just Bought 361% More Shares (Simply Wall St.)
Dec-05-22 07:30AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -10.37%
Dec-01-22 07:00AM	Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 3:30 pm Eastern time (GlobeNewswire)
Nov-29-22 11:00AM	Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimers Disease Patients from ACT-AD Phase 2 Study at CTAD Conference (GlobeNewswire)
Nov-28-22 07:00AM	Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -5.02%
Nov-21-22 07:00AM	Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimers Disease (CTAD) Conference (GlobeNewswire)
Nov-16-22 07:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference (GlobeNewswire)
Nov-10-22 04:05PM	Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates (GlobeNewswire) +7.97%
Nov-09-22 07:00AM	Athira Pharma to Present at Stifel 2022 Healthcare Conference (GlobeNewswire) -7.07%
Nov-07-22 07:00AM	Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference (GlobeNewswire)
Oct-30-22 08:29AM	Athira Pharma, Inc. (NASDAQ:ATHA) has caught the attention of institutional investors who hold a sizeable 47% stake (Simply Wall St.)
Oct-17-22 07:00AM	Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients Following Independent, Unblinded Interim Analysis (GlobeNewswire) +9.03%
Sep-16-22 08:14AM	Multiple insiders bought Athira Pharma, Inc. (NASDAQ:ATHA) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Sep-06-22 03:22PM	Athira Outlines Possible Comeback For Alzheimer's Candidate (Benzinga)
07:00AM	Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients (GlobeNewswire)
Aug-20-22 08:01AM	Athira Pharma (NASDAQ:ATHA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-15-22 04:05PM	Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates (GlobeNewswire)
Aug-03-22 11:28AM	Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients at the Alzheimer's Association International Conference 2022 (GlobeNewswire)
Aug-02-22 03:30PM	Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022 (GlobeNewswire)
Jul-25-22 07:00AM	Athira Pharma to Present Clinical and Preclinical Data at Alzheimers Association International Conference 2022 (GlobeNewswire)
Jul-08-22 04:19PM	Rapid Micro and Athira Pharma Stock See Action From Activist Investors (Barrons.com)
Jun-22-22 04:49PM	Athira Pharma's stock plummets after disappointing drug trial results (American City Business Journals) -66.27%
01:29PM	Athira Pharma stock loses two-thirds of its value after study of Alzheimer's treatment misses primary endpoint (MarketWatch)
11:31AM	Why Athira Pharma Stock Imploded Today (Motley Fool)
08:25AM	Athira says its Alzheimer's treatment did not meet endpoint in mid-stage trial; stock falls 68% (MarketWatch)
08:21AM	Athira Pharma Shares Fall To 52-Week Low - Read Why (Benzinga)
07:00AM	Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimers Disease (GlobeNewswire)
Jun-07-22 07:00AM	Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research (GlobeNewswire)
May-22-22 10:43AM	What Kind Of Investors Own Most Of Athira Pharma, Inc. (NASDAQ:ATHA)? (Simply Wall St.)
May-19-22 12:06PM	Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting (GlobeNewswire)
May-17-22 05:39AM	Athira shareholder suspends push for board control days before shareholders' meeting (American City Business Journals)
May-16-22 04:49PM	Athira Issues Statement in Response to Richard A. Kaynes Suspension of His Proxy Contest (GlobeNewswire)
07:00AM	Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
May-12-22 04:05PM	Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire) -5.46%
May-11-22 04:15PM	Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting (GlobeNewswire) -9.17%
May-09-22 07:00AM	Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimers Disease (GlobeNewswire)
May-05-22 12:04PM	Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote FOR All of Athiras Highly Qualified Director Nominees (GlobeNewswire) -6.29%
08:00AM	Athira Mails Letter to Shareholders Emphasizing the Companys Strong Position and Qualified Board as it Enters Pivotal Chapter (GlobeNewswire)
May-04-22 06:46PM	Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athiras WHITE Proxy Card (GlobeNewswire)
Apr-28-22 12:54AM	Athira leadership braces for challenge as shareholders' meeting approaches (American City Business Journals)
Apr-26-22 08:00AM	Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership (GlobeNewswire)
Apr-20-22 09:02AM	Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment (GlobeNewswire)
Apr-12-22 12:45AM	Athira co-founder says departure of Leen Kawas 'casts doubt' on biotech's future (American City Business Journals)

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Litton Mark James	Chief Executive Officer	Jan 05 '24	Sale	2.91	4,820	14,026	144,397	Jan 08 04:40 PM
Worthington Mark	General Counsel	Jan 05 '24	Sale	2.91	2,412	7,019	34,452	Jan 08 04:38 PM
Lenington Rachel	Chief Operating Officer	Jan 05 '24	Sale	2.91	2,412	7,019	13,395	Jan 08 04:35 PM
PERCEPTIVE ADVISORS LLC	Director	Dec 29 '23	Buy	2.38	163,954	390,211	5,402,964	Dec 29 05:24 PM
PERCEPTIVE ADVISORS LLC	Director	Dec 28 '23	Buy	2.44	409,598	999,419	5,239,010	Dec 29 05:24 PM
PERCEPTIVE ADVISORS LLC	Director	Dec 27 '23	Buy	2.28	32,134	73,266	4,829,412	Dec 29 05:24 PM
Gengos Andrew	See Below	Jun 07 '23	Buy	3.43	15,000	51,445	80,012	Jun 09 05:06 PM
Gengos Andrew	See Below	Jun 05 '23	Buy	3.00	45,000	135,150	65,012	Jun 06 07:36 PM
MOEBIUS HANS	Chief Medical Officer	Jun 02 '23	Option Exercise	1.35	7,882	10,641	81,482	Jun 06 07:35 PM
Gengos Andrew	See Below	Jun 02 '23	Buy	2.82	20,012	56,422	20,012	Jun 06 07:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATHA

Athira Pharma Inc

Upgrade your FINVIZ experience